Infection Complications in Febrile Chimeric Antigen Receptor (CAR)-T Recipients During the Peri-CAR-T Cell Treatment Period Examined Using Metagenomic Next-generation Sequencing (mNGS)

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2022 Jan 15

PMID 35032364

Authors

Jiali Nie

Li Yang

Liang Huang

Lili Gao

Ken He Young

Jehane Michael Le Grange

Xingcheng Yang

Jia Wei

Min Xiao

Jianfeng Zhou

Affiliations

Soon will be listed here.

Citing Articles

Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.

An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W Cancer Med. 2024; 13(12):e7372.

PMID: 38923216 PMC: 11196838. DOI: 10.1002/cam4.7372.

A clinical predictive model for pre-transplantation colonization and relevance for clinical outcomes in patients receiving allogeneic hematopoietic stem cell transplantation.

Zhang Y, Wu W, Xu J, Tang Z, Li S, Li L Microbiol Spectr. 2024; 12(2):e0203923.

PMID: 38189331 PMC: 10846164. DOI: 10.1128/spectrum.02039-23.

CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and....

Li S, Ge J, Zhou S, Zhu W, Han Y, Chen S Clin Transl Med. 2023; 13(10):e1459.

PMID: 37882317 PMC: 10600828. DOI: 10.1002/ctm2.1459.

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.

Zhang T, Tian W, Wei S, Lu X, An J, He S Exp Hematol Oncol. 2023; 12(1):66.

PMID: 37501090 PMC: 10375673. DOI: 10.1186/s40164-023-00426-x.

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.

Wang S, Liu A, Wang N, Wang Y, Zhang A, Wang L Front Pediatr. 2023; 10:1100404.

PMID: 36727001 PMC: 9885096. DOI: 10.3389/fped.2022.1100404.

References

Wei J, Zhu X, Mao X, Huang L, Meng F, Zhou J . Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer. 2019; 7(1):315. PMC: 6868854. DOI: 10.1186/s40425-019-0790-y. View

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

Miao Q, Ma Y, Wang Q, Pan J, Zhang Y, Jin W . Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing When Applied to Clinical Practice. Clin Infect Dis. 2018; 67(suppl_2):S231-S240. DOI: 10.1093/cid/ciy693. View

Oved J, Barrett D, Teachey D . Cellular therapy: Immune-related complications. Immunol Rev. 2019; 290(1):114-126. PMC: 7041800. DOI: 10.1111/imr.12768. View

Flores-Trevino S, Bocanegra-Ibarias P, Camacho-Ortiz A, Morfin-Otero R, Salazar-Sesatty H, Garza-Gonzalez E . biofilm: its role in infectious diseases. Expert Rev Anti Infect Ther. 2019; 17(11):877-893. DOI: 10.1080/14787210.2019.1685875. View

Hill J, Li D, Hay K, Green M, Cherian S, Chen X . Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2017; 131(1):121-130. PMC: 5755046. DOI: 10.1182/blood-2017-07-793760. View

Vora S, Waghmare A, Englund J, Qu P, Gardner R, Hill J . Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infect Dis. 2020; 7(5):ofaa121. PMC: 7221263. DOI: 10.1093/ofid/ofaa121. View

Wudhikarn K, Palomba M, Pennisi M, Garcia-Recio M, Flynn J, Devlin S . Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020; 10(8):79. PMC: 7405315. DOI: 10.1038/s41408-020-00346-7. View

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

10.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View